Haemoglobin-based oxygen carriers: Is the benefit worth the risk?

British Journal of Hospital Medicine

Volumn 70, Issue 1, 2009, Pages 26-30

  Mackenzie, Colin F ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 64549115997     PISSN: 17508460     EISSN: None     Source Type: Journal    
DOI: 10.12968/hmed.2009.70.1.37691     Document Type: Conference Paper

References (30)

1. America's Blood Centers (2008) ABC blood supply status report Oct. 30 2008. (http://members.americasblood.org/plsql/ecat/supplymonitor-pkg.web-report accessed 30 October 2008)
2. Carless PA, Henry DA, Moxley AJ (2006) Cell salvage for minimizing perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 18: CD 001888
3. Center For Biologies Evaluation And Research (2008) Safety of Hemoglobin-Based Oxygen Carriers (HBOCs) (http://www.fda. gov/cber/minutes/ hboc042908t.htm accessed 24 November 2008)
4. Culleton BF, Manns BJ, Zhang J (2006) Impact of anemia on hospitalization and mortality in older adults. Blood 107: 3841-6
5. Fergusson DA, McIntyre L (2008) The future of clinical trials evaluating blood substitutes. JAMA 299: 2324-6
6. Gould SA (2008) Clinical development of PolyHeme. In: Safety of Hemoglobin-Based Oxygen Carriers (HBOCs). Food and Drug Administration, Bethesda, Maryland (www.fda.gov/cber/minutes/hboc042908t.htm accessed 10 December 2008)
7. Greenburg AG (2008) Biopure HBOC-201. In: Safety of Hemoglobin-Based Oxygen Carriers (HBOCs). Food and Drug Administration, Bethesda, Maryland (www.fda.gov/cber/minutes/hboc042908t.htm accessed 10 December 2008)
8. Hebert PC, Wells G, Blajchman MA et al (1999) A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med 340: 409-17
9. Hospital Liaison Committee (2000) Questions from readers. The Watchtower June 15: 29-31
10. Jahr JS, Mackenzie CF, Pearce LB et al (2008) HBOC-201 as an alternative to blood transfusion: efficacy and safety evaluation in a multicenter phase iii trial in elective orthopedic surgery. J Trauma 64: 1484-92
11. Keipert PE (2008) Development of Hemospan. In: Safety of Hemoglobin-Based Oxygen Carriers (HBOCs). Food and Drug Administration, Bethesda, Maryland (www.fda.gov/cber/minures/hboc042908t.htm accessed 10 December 2008)
12. Keipert PE, Olofsson C, Winslow RM (2008) Hemoglobin-based blood substitutes and risk of myocardial infarction and death. (Letter). JAMA 300: 1295-6
13. Koch CG, Li L, Sessler DI, Figueroa P (2008) Duration of red cell storage and complications after cardiac surgery. N Engl J Med 358: 1229-39
14. Levien LJ, Hodgson RE, James MFM (2008) Hemoglobin-based blood substitutes and risk of myocardial infarction and death. (Letter). JAMA 300: 1295
15. Lewis RJ, Frost N (2008) Hemoglobin-based blood substitutes and risk of myocardial infarction and death. (Letter). JAMA 300: 1296
16. Mackenzie CF, Bucci C (2002) Artificial oxygen carriers for trauma: myth or reality? Hosp Med 65: 582-8
17. Mackenzie CF, Shander A (2008) What to do if no blood is available but the patient is bleeding. SAJAA 14: 39-43
18. Marik PE, Corwin HL (2008) Efficacy of red blood cell transfusion in the critically ill. A systematic review of the literature. Crit Care Med 36 : 2667-74
19. Mullon J, Giacope G, Clagett C et al (2000) Transfusion of polymerized bovine hemoglobin in a patient with severe autoimmune hemolytic anemia. N Engl J Med 342: 1638-43
20. Natanson C, Kern SJ, Lurie P et al (2008) Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis. JAMA 299: 2304-12
21. National Blood Data Resource Center (2005) Comprehensive report on blood collection and transfusion in the United States, (www.aabb.org/apps/docs/ 05nbcusrpt.pdf accessed 28 September 2008)
22. Olofsson C, Ahl T, Johansson T (2006) A multi-center clinical study of the safety and activity of maleimide-polyethylene-glycolhemoglobin (Hemospan) in patients undergoing major orthopedic surgery. Anesthesiology 105: 1153-63
23. Patel MB, Feinstein AJ, Saenz AD et al (2006) Pre-hospital HBOC- 201 after traumatic brain injury and hemorrhagic shock in swine. J Trauma 61: 46-56
24. Sarani B, Gracias V (2008) Hemoglobin-based blood substitutes and risk of myocardial infarction and death. (Letter). JAMA 300: 1297-8
25. Sauaia A, Moore EE, Banerjee A (2008) Hemoglobin-based blood substitutes and risk of myocardial infarction and death. (Letter). JAMA 300: 1297
26. Shander A, Goodnough LT (2006) Objectives and limitations of bloodless medical care. Curr Opin Hematol 13: 462-70
27. Shander A, Javidroozi M, Thompson G (2008) Hemoglobin-based blood substitutes and risk of myocardial infarction and death. (Letter). JAMA 300: 1296-7
28. Sloan EP, Koenigsberg M, Gens D et al (1999) Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: a randomized controlled efficacy trial. JAMA 282:1857-64
29. Vamvakas EC (1996) Epidemiology of red cell utilization. Trans Med Rev 10: 44-61
30. Winslow RM (2003) Alternative oxygen therapeutics: Products, status of clinical trials and future prospects. Curr Hematol Reports 2: 503-10